Cullinan Therapeutics, Inc. (CGEM): Insider Trading, Congress Trades & Research | Tormere

CGEM

$15.51+6.74%website ↗⬇ financials (.py)

Cullinan Therapeutics, Inc.

Market Cap

$953M

Live price × shares (2026-09-16)

Sector

Health Care

Industry

Biotechnology

Beta (raw)

-0.01

60mo monthly vs SPY

P/E (TTM)

N/M

Price / TTM net income

P/S (TTM)

—

Price / TTM revenue

P/B

3.0

Price / stockholders equity

EV/EBITDA

—

TTM

Price Chart

Loading…

Signals

Insider Velocity

Market & Alt Data

News

15

recent articles

Analyst Consensus

Strong Buy

19 analysts

Velocity Score

3.47x

Sell Rate (90d)

511.11/mo

Sell Baseline

353.03/mo

Unique Sellers (90d)

1

Sort by

Type

Trade Date	Filed	Owner	Role	Type	Shares	Price	Value	Owned After
2026-09-08	2026-09-10	Michaelson Jennifer	Chief Scientific Officer	Sale	8,000	$21.57	$173K	158.8K	View
2026-08-13	2026-08-14	Michaelson Jennifer	Chief Scientific Officer	Sale	30.0K	$20.26	$608K	162.8K	View
2026-07-06	2026-07-07	Michaelson Jennifer	Chief Scientific Officer	Sale	8,000	$17.82	$143K	162.8K	View
2026-05-05	2026-05-06	Michaelson Jennifer	Chief Scientific Officer	Sale	8,000	$14.62	$117K	166.8K	View
2026-03-05	2026-03-09	Michaelson Jennifer	Chief Scientific Officer	Sale	8,000	$15.68	$125K	170.8K	View

1–5 of 15

1 / 3

Reporting Insiders

Recent News

Cullinan Management Advances NDA for Zipalertinib Combination

The Globe and Mail · 2026-10-03

CGEM Reiterated by HC Wainwright & Co. -- Price Target Maintained at $35

GuruFocus · 2026-10-02

Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Stock Has Consensus Price Target of $33.71 According to Analysts

MarketBeat · 2026-10-02

HC Wainwright & Co. Reiterates Buy on Cullinan Therapeutics, Maintains $35 Price Target

Benzinga · 2026-10-02

Cullinan Therapeutics, Inc. (CGEM) Stock Price, News, Quote & History

Yahoo! Finance Canada · 2026-10-02

Reported Earlier, Cullinan Therapeutics Initiates NDA Submission For Zipalertinib Plus Chemotherapy In First-Line EGFR Exon 20 Insertion NSCLC Under FDA RTOR Program After Phase 3 REZILIENT3 Trial Met Primary Endpoint

Benzinga · 2026-10-02

Cullinan Therapeutics, Inc. (CGEM) stock price, news, quote and history

Yahoo Finance Australia · 2026-10-02

New Drug Application Submission Initiated for Zipalertinib Plus Chemotherapy in First-Line EGFR Exon 20 Insertion Mutation NSCLC for Review Under FDA Real-Time Oncology Review Program

Yahoo · 2026-10-01

Discipline and Rules-Based Execution in CGEM Response

Stock Traders Daily · 2026-09-30

Cullinan Therapeutics: Compelling Pullback For CLN-978's Potential In Autoimmune Diseases

SeekingAlpha · 2026-09-29

Cullinan Therapeutics Eyes December Data Catalyst for CLN-978 and CLN-049

Yahoo · 2026-09-28

Cullinan Therapeutics (CGEM) Expects Three T Cell Engager Data Readouts In Q4 2026

Yahoo · 2026-09-26

HC Wainwright & Co. Maintains Buy on Cullinan Therapeutics, Raises Price Target to $35

Benzinga · 2026-09-25

BTIG Reiterates Buy on Cullinan Therapeutics, Maintains $40 Price Target

Benzinga · 2026-09-25

CGEM Stock Extends Losses After Cullinan Delays Arthritis Update To December — Zipalertinib Safety Worries Linger

Yahoo · 2026-09-24

Informational purposes only, not investment advice.

Recent Insider Activity (Form 4) — Last 5

Date	Insider	Type	Shares	Value
2026-09-08	Michaelson Jennifer	S	8,000	$172,560
2026-08-13	Michaelson Jennifer	S	30,000	$607,800
2026-07-06	Michaelson Jennifer	S	8,000	$142,560
2026-05-05	Michaelson Jennifer	S	7,800	$113,880
2026-05-05	Michaelson Jennifer	S	200	$3,116